Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
BOSTON, Nov. 09, 2022 – Cue Biopharma (Nasdaq: CUE) announced presentations at two investor conferences this November. The Stifel Healthcare Conference will be held on November 15-16, and the Jefferies London Healthcare Conference will take place November 15-17. Cue Biopharma will discuss updates on CUE-101, part of its IL-2-based CUE-100 series, in a Phase 1 trial for HPV+ recurrent/metastatic head and neck cancer, along with CUE-102 for WT1 positive cancers. CEO Daniel Passeri will present both sessions, with webcasts available post-event.
BOSTON, Nov. 07, 2022 – Cue Biopharma, a clinical-stage biopharmaceutical company, will host a conference call and webcast on November 14, 2022, at 4:30 p.m. EST. The event will provide a business update, including a summary of data from the Society for Immunotherapy of Cancer’s 37th Annual Meeting. Key highlights include ongoing clinical trials of its lead biologic, CUE-101, for recurrent/metastatic HPV+ head and neck cancer, and updates on its second candidate, CUE-102. Access to the webcast is available on the company’s website.
Cue Biopharma (Nasdaq: CUE) announced three poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), scheduled for November 8-12, 2022, in Boston. The presentations focus on CUE-101 and CUE-102, innovative biologics targeting specific cancer types. Dr. Christine Chung will present on CUE-101 for HPV16+ head and neck cancer, while Dr. Steven Margossian discusses CUE-102 for WT1-positive cancers. All posters will also be available as virtual e-posters and on the company’s website.
Cue Biopharma (Nasdaq: CUE) announced that the FDA has granted Fast Track designation to its lead drug candidate, CUE-101, for treating HPV16+ recurrent/metastatic head and neck squamous cell carcinoma. This designation highlights the urgent need for targeted therapies in this patient population. CUE-101 has shown favorable tolerability and initial anti-tumor activity in clinical trials, and a registrational trial for monotherapy is anticipated by mid-2023. The Fast Track process may allow for expedited development and review of the drug.
Cue Biopharma (CUE) is set to present at two scientific conferences this September. The first event, The Promise of Interleukin-2 Therapy, runs from September 14-17 in Paris. Matteo Levisetti, M.D. will present data on CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The second event, Next Generation Protein Therapeutics Summit, takes place September 28-30 in Boston, where Anish Suri, the company’s CSO, will highlight the Immuno-STAT platform and its IL-2 based candidates. These advancements reflect Cue Biopharma’s commitment to innovative cancer therapies.
Cue Biopharma (CUE) has initiated a Phase 1 dose escalation study for CUE-102, targeting WT1-positive recurrent/metastatic cancers. The first patient has been dosed with a starting dose of 1 mg/kg, reflecting a step forward in demonstrating the Immuno-STAT™ platform's potential. CUE-102 shows promise in selectively activating tumor-specific T cells, with preclinical studies indicating significant immune response. The trial aims to enroll around 50 patients and examines safety, tolerability, and anti-tumor activity.
Cue Biopharma reported its second quarter 2022 financial results, highlighting a significant decrease in collaboration revenue to $26,000, down from $2.7 million in Q2 2021. Research and development expenses rose to $9.6 million, while general and administrative expenses fell to $3.8 million. The company extended its cash runway with $23.6 million raised from an equity offering. Notably, the FDA accepted an IND for CUE-102, and a Phase 1 trial is underway, focusing on various cancers.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma (Nasdaq: CUE) announced its participation in the Guggenheim I&I Spotlight Series on Treg-based Therapies, scheduled for July 13, 2022, from 9:00 a.m. to 9:45 a.m. EDT. This event highlights the company's innovative approach to cancer treatment through its Immuno-STAT™ platform, which modulates T cells within the body. A live and archived webcast will be available on Cue Biopharma's website.
For more details, visit www.cuebiopharma.com.
Cue Biopharma (Nasdaq: CUE) announced participation in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2022. The presentation will focus on ongoing clinical trials and corporate development initiatives. The event will be webcast live from 1:00 p.m. to 1:25 p.m. EDT and archived for 30 days. Cue Biopharma is known for its innovative Immuno-STAT™ platform, aimed at targeted T cell engagement for cancer treatment. The company is headquartered in Boston and focuses on developing injectable biologics.
Cue Biopharma announced its participation in the Jefferies Healthcare Conference scheduled for June 8-10, 2022. The company will present updates on its lead candidate, CUE-101, currently in a Phase 1b trial for HPV16+ head and neck cancer, and its second candidate, CUE-102, which received FDA approval for an IND application. CUE-102 will undergo Phase 1 trials for WT1-positive cancers. The presentation is set for June 10 at 1:45 p.m. EDT, with webcasts available for 30 days.